| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.04.23 | Immix Biopharma - Pipeline momentum continues in FY23 | 501 | Edison Investment Research | Immix Biopharma's FY22 results reflected a busy period as management ramped up clinical activity across multiple programs. In a major development, Immix expanded its portfolio with the in-licensing... ► Artikel lesen | |
| 05.04.23 | Molecure - Clinical progression ahead in FY23 | 542 | Edison Investment Research | Molecure is entering FY23 with two active clinical programmes. OATD-01, the company's lead proprietary asset, is in development for the treatment of sarcoidosis, but management expects to expand into... ► Artikel lesen | |
| 05.04.23 | Light Science Technologies Holdings - Proposed £1.5m placing and subscription | 337 | Edison Investment Research | Light Science Technologies Holdings has conditionally raised £1.5m (gross) through a placing and private subscription at 1p/share. The company also intends to raise up to £0.5m (gross) at 1p/share via... ► Artikel lesen | |
| 05.04.23 | Light Science Technologies Holding - Proposed £1.5m placing and subscription | 312 | Edison Investment Research | Light Science Technologies Holdings has conditionally raised £1.5m (gross) through a placing and private subscription at 1p/share. The company also intends to raise up to £0.5m (gross) at 1p/share via... ► Artikel lesen | |
| 05.04.23 | IP Group - Priority companies making progress in 2022 | 521 | Edison Investment Research | IP Group's NAV per share came in at 132.9p at end-2022, only 2% below the end-June 2022 level. The NAV decline during 2022 was primarily due to the £428.5m loss from listed holdings (before foreign... ► Artikel lesen | |
| 05.04.23 | Utilico Emerging Markets Trust - Companies' operational strength not priced in | 367 | Edison Investment Research | Utilico Emerging Markets Trust's (UEM's) manager Charles Jillings, at value-focused ICM Group, is excited about the prospects for the trust as he strongly believes that the operational strength of investee... ► Artikel lesen | |
| 05.04.23 | Paradigm Biopharma - Potential for disease-modifying kOA treatment | 433 | Edison Investment Research | Paradigm has announced day 168 (six-month) data from the PARA_OA_008 trial, which is evaluating injectable pentosan polysulfate sodium (iPPS) as a potentially disease-modifying treatment for knee osteoarthritis... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 357 |
| EVOTEC | 323 |
| TUI | 239 |
| NVIDIA | 195 |
| DEUTSCHE BANK | 191 |
| BAYER | 174 |
| PLUG POWER | 157 |
| RHEINMETALL | 148 |
| NEL | 146 |
| SIEMENS ENERGY | 131 |
| COMMERZBANK | 117 |
| BARRICK GOLD | 116 |
| TESLA | 112 |
| BASF | 111 |
| VOLKSWAGEN | 109 |
| RWE | 102 |
| DEUTSCHE LUFTHANSA | 98 |
| BYD | 96 |
| ALLIANZ | 92 |
| DEUTSCHE TELEKOM | 91 |
| MERCEDES-BENZ | 90 |
| RENK GROUP | 88 |
| E.ON | 83 |
| HEIDELBERGER DRUCK | 80 |
| REDCARE PHARMACY | 79 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
